ClinicalTrials.gg
Not yet recruitingNCT07856940Updated Oct 5, 2026

GPT-Based Digital Assistant Support During Treatment for Induced Abortion or Missed Abortion

An interventional study of GPT-Based Digital Assistant in Missed Abortion, Early Pregnancy Loss and Abortion in First Trimester, sponsored by Wolfson Medical Center. Not yet recruiting at 1 site in Israel. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Wolfson Medical Center · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Abortion, Missed with a site in Israel — 2 open to participants now, 2 under way, none of them phase 3. Abortion, Missed · Israel.

Started
2026
the only one that year
No phase
6 of 11
2 open now
Registered
11th of 11
by date
Lead sponsor
2 of 11
Wolfson Medical Center

Among the 11 studies in Abortion, Missed with a site in Israel, this one is the only one that started in 2026, is one of 6 with no phase, and was the 11th registered.

Abortion, Missed

48 studies on the registry are indexed under Abortion, Missed; 10 are open to participants now.

Browse Abortion, Missed studies →

Open to participants now

2 of the 11 studies in Abortion, Missed with a site in Israel are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 5 Abortion, Missed studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Abortion, Missed with a site in Israel, or all of them as a file.
02

Study summary

We have developed a digital assistant based on GPT (Generative Pre-trained Transformer) technology, trained specifically to provide empathetic, medically accurate, and guideline-based responses in Hebrew, tailored to the clinical protocols used in our clinic.

The goal of this interventional study is to learn about the feasibility, usability, and acceptability of a GPT-based digital assistant for patients undergoing medication abortion or treatment for missed abortion.

The study aims to assess use of the digital assistant, patient-reported usability, usefulness and satisfaction, perceived support, comprehension of treatment instructions, and decisions about contacting medical staff.

Participants already receiving standard care for medication abortion or missed abortion at the clinic will be offered access to the digital assistant immediately after enrollment. They may use the assistant freely at home throughout their treatment process and will complete baseline and follow-up surveys about their experience, emotional state, and any additional contacts with the clinic.

Read the detailed description

Medication abortion and treatment for missed abortion can be emotionally and physically demanding experiences. Patients may experience confusion, anxiety, and isolation during the home phase of treatment, and clinical instructions may be difficult to understand or follow during moments of stress or pain. Accessible, timely, and patient-centered information may help support patients throughout this process.

This prospective, single-arm, open-label, interventional feasibility study will assess the feasibility, usability, and acceptability of a GPT-based digital assistant designed to support patients undergoing induced abortion or treatment for missed abortion. The assistant is designed to provide empathetic, guideline-based information in Hebrew, tailored to the clinical protocols used in the clinic. It provides information in plain language and directs patients to the clinic or emergency care when appropriate.

Approximately 100 Hebrew-speaking patients undergoing induced abortion at up to 9 weeks of gestation or treatment for missed abortion at up to 12 weeks of gestation at Wolfson Medical Center will be enrolled during their initial clinic visit. After providing informed consent, participants will receive access to the digital assistant alongside standard clinical care. They may use the assistant as needed throughout the treatment process until the follow-up visit. There is no randomization or comparator group.

Baseline data will include demographic characteristics, previous abortion experience, and expectations regarding the digital assistant. Follow-up data will be collected through a study-specific questionnaire assessing assistant use, ease of use, usefulness, overall satisfaction, self-reported emotional state, perceived support, comprehension of treatment instructions, whether participants contacted medical staff and the type of contact, and whether they decided not to contact medical staff after receiving an answer from the assistant. Open-ended feedback will also be collected.

The study will evaluate feasibility and usage rates, patient satisfaction, perceived emotional support, and comprehension of treatment instructions. Participant feedback will be used to identify opportunities for improvement and explore potential integration into reproductive care.

The assistant is intended to supplement standard clinical information and support, rather than replace professional medical assessment or emergency services. Study data will be anonymized and stored securely in accordance with the approved protocol.

03

Conditions studied

  • Missed Abortion
  • Early Pregnancy Loss
  • Abortion in First Trimester
  • Abortion, Medical

Keywords

  • Medical abortion
  • Artificial Intelligence
  • GPT
  • Missed abortion
  • Early Pregnancy Loss
  • Digital Assistant
  • Chatbot
  • Feasibility Study
  • Patient Satisfaction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Undergoing medical abortion (up to 9 weeks gestation) or treatment for missed abortion (up to 12 weeks gestation)
  • Hebrew-speaking
  • Signed

Exclusion criteria

Exclusion Criteria:

  • No access to a smartphone or internet at home
  • Non-Hebrew speakers
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    GPT-Based Digital Assistant Support

    Participants undergoing treatment for induced or missed abortion will receive access to a Hebrew-language GPT-based digital assistant upon enrollment, in addition to standard clinical care. Participants may use the assistant as needed until their follow-up visit. The assistant is designed to provide plain-language information about the treatment process, clarify clinical instructions, offer emotional support, and direct participants to the clinic or emergency services when appropriate. It supplements, rather than replaces, professional medical care.

    Other: GPT-Based Digital Assistant

Interventions

  • OtherGPT-Based Digital Assistant

    a digital assistant based on GPT (Generative Pre-trained Transformer) technology, trained specifically to provide empathetic, medically accurate, and guideline-based responses in Hebrew, tailored to the clinical protocols used in our clinic. The assistant is designed to support patients throughout the medication abortion or missed abortion process, from the time of first medication until the follow-up visit. It offers culturally sensitive information in plain language, referring to the clinic or emergency care as needed.

06

What researchers measure

Primary outcomes

  1. Feasibility and usage rates of the digital assistant

    Feasibility will be assessed by the percentage of follow-up questionnaire respondents who report using the GPT-based digital assistant during the treatment process. Use will be assessed by a yes/no question in the study-specific, non-validated follow-up questionnaire. The number of respondents and the number of enrolled participants without follow-up data will also be reported.

    Time frame: From enrollment to follow-up at 2 weeks

  2. Frequency of digital assistant use

    Frequency of use will be assessed among participants who report using the GPT-based digital assistant, as assessed using the study-specific, non-validated follow-up questionnaire. Participants select one of four categories: once, 2-3 times, 4-5 times, or more than 5 times. The percentage of users in each category will be reported.

    Time frame: From enrollment through follow-up at 2 weeks

  3. Patient satisfaction, usability, and perceived usefulness

    Patient experience will be assessed among participants who used the GPT-based digital assistant, using three items in the study-specific, non-validated follow-up questionnaire: ease of use, perceived usefulness of the information, and overall satisfaction. Each item is rated from 1 (do not agree at all) to 5 (strongly agree). Higher scores indicate greater ease of use, usefulness, or satisfaction. Each item will be reported separately; no combined score will be calculated.

    Time frame: at 2 weeks after enrollment

  4. Patient-reported decision not to contact medical staff after using the assistant

    The percentage of assistant users who report an occasion when they considered contacting medical staff but felt that contact was unnecessary after receiving a response from the GPT-based digital assistant will be assessed using the study-specific, non-validated follow-up questionnaire. Response options are yes, no, and unsure. The distribution of responses will be reported.

    Time frame: at 2 weeks after enrollment

  5. Perceived support and availability of answers

    Perceived support will be assessed using two items in the study-specific, non-validated questionnaire: having sufficient support to cope with the process, and being able to obtain answers to questions when needed. Each item is rated from 1 (do not agree at all) to 5 (strongly agree), with higher scores indicating greater perceived support or availability of answers. Baseline and follow-up responses will be reported separately for each item.

    Time frame: At baseline before first use and at 2 weeks after enrollment.

  6. Self-reported comprehension of treatment instructions

    Self-reported comprehension will be assessed using three items in the study-specific, non-validated questionnaire addressing how and when to take medications, expected symptoms, and when to seek medical assistance. Each item is rated from 1 (do not agree at all) to 5 (strongly agree), with higher scores indicating greater perceived comprehension. Baseline and follow-up responses will be reported separately for each item.

    Time frame: At baseline before first use and at 2 weeks after enrollment.

Secondary outcomes

  1. Participant suggestions for improvement

    Suggestions for improvement will be collected using the open-ended follow-up question asking participants what one thing they would change or improve in the GPT-based digital assistant. Responses will be summarized qualitatively and grouped into recurring themes.

    Time frame: at 2 weeks after enrollment

  2. Insights into integration into reproductive care

    An exploratory qualitative synthesis of participant suggestions for improvement will identify themes potentially relevant to integrating the digital assistant into routine reproductive care. This assessment will use responses to the open-ended follow-up question asking what participants would change or improve in the assistant and will not generate a numerical score.

    Time frame: at 2 weeks after enrollment

07

Study locations

1 site
08

References and documents

Publications

  • Wilson-Lowe RV, Purcell C, Lewis R, McDaid L. Seeking support for abortion online: a qualitative study of women's experiences. BMJ Sex Reprod Health. 2024 Jul 12;50(3):172-177. doi: 10.1136/bmjsrh-2023-202083. PubMed 38336468 ↗
  • Lewandowska M, Scott R, Meiksin R, Reiter J, Salaria N, Lohr PA, Cameron S, Palmer M, French RS, Wellings K; SACHA Study Team. How can patient experience of abortion care be improved? Evidence from the SACHA study. Womens Health (Lond). 2024 Jan-Dec;20:17455057241242675. doi: 10.1177/17455057241242675. PubMed 38794997 ↗
  • Upadhyay UD, Cockrill K, Freedman LR. Informing abortion counseling: an examination of evidence-based practices used in emotional care for other stigmatized and sensitive health issues. Patient Educ Couns. 2010 Dec;81(3):415-21. doi: 10.1016/j.pec.2010.08.026. PubMed 20926226 ↗
  • Koenig LR, Ko J, Valladares ES, Coeytaux FM, Wells E, Lyles CR, Upadhyay UD. Patient Acceptability of Telehealth Medication Abortion Care in the United States, 2021-2022: A Cohort Study. Am J Public Health. 2024 Feb;114(2):241-250. doi: 10.2105/AJPH.2023.307437. Epub 2024 Jan 18. PubMed 38237103 ↗
  • Shahrokhi SN, Salmani H, Ahmadi M. The Role of Electronic Health Tools in Unwanted Pregnancy Prevention, Abortion and Post-Abortion Follow-Up: A Systematic Review. Iran J Nurs Midwifery Res. 2023 Sep 8;28(5):487-503. doi: 10.4103/ijnmr.ijnmr_312_20. eCollection 2023 Sep-Oct. PubMed 37869688 ↗
  • Seymour JW, Goode BA, Guerrero P, Campos AM, Kyles K, Dreyfus-Pai P, Baum SE. Emotional, informational, and decision-making support needs among people seeking abortion in the US: perspectives from All-Options Talkline callers. Sex Reprod Health Matters. 2023 Dec;31(1):2248742. doi: 10.1080/26410397.2023.2248742. Epub 2023 Sep 20. PubMed 37728428 ↗

Individual participant data

Plan to share: No — There is no plan to share individual participant data. Study findings will be disseminated in aggregate form through scientific publications and presentations.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Jan 2027, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 5, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Jan 30, 2027
CompletionEst.
Jan 30, 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07856940
Responsible party
Liron Koren Arkin (Senior OB/GYN, Wolfson Medical Center) — Principal investigator
First posted
Oct 5, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Jan 30, 2027 (estimated)
Completion
Jan 30, 2027 (estimated)
Last update
Oct 5, 2026

Study contacts

Liron Koren Arkin, MD
Contact
lrnkoren@gmail.com
+972-545960296
Liron Koren Arkin
principal investigator · Edith Wolfson Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion